Answers are grounded in this paper and cite their sources.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective drugs for the treatment of type 2 diabetes mellitus and the management of obesity. Although these medications are generally safe, concerns have emerged regarding the possible link between GLP-1 RA use and thyroid cancer, particularly medullary thyroid carcinoma. This systematic review and meta-analysis aimed to investigate the association between GLP-1 RA use and the risk of all types of thyroid cancer. Materials and Methods: A systematic search was performed using Embase, PubMed/Medline, the US Clinical Trials Registry, and Google Scholar up to July 2024 for randomized controlled trials (RCTs) on GLP-1 RAs in diabetic or overweight/obese adults with at least 24 weeks of treatment and reported thyroid cancer incidence. A random-effects meta-analysis model was used to calculate the odds ratio (OR) and the 95% confidence interval (CI) of the risk of thyroid cancer in the GLP-1 RA group compared to control groups. Assessments of subgroup analyses and publication bias were also performed. Results: Of the 44 RCTs in the meta-analysis, which involved 84,472 study participants, there was no significant association between the use of GLP-1 RAs and thyroid cancer when compared to control groups (OR = 1.11; 95% CI = 0.74–1.69). In the subgroup analysis based on the comparators, population, and type of GLP-1 RAs, no significant association was found to be associated with the risk of thyroid cancer. Conclusion: The analysis showed no increased risk of thyroid cancer with GLP-1 RAs use. However, large-scale, long-term studies are necessary given the very low incidence of thyroid cancer and variations in the duration of treatment.
No takes yet. Share an insight, caveat, or question.
Khawandanah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: